Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $17.78 is 113.70% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 18.525||$ 23.43|
|Low:||$ 17.76||$ 8.32|
Company Description (as filed with the SEC)
We are a commercial-stage biotherapeutics company focused on the global biosimilar market. Biosimilars are a class of protein-based therapeutics with high similarity to approved originator products on the basis of various structural, physicochemical and biological properties, as well as in terms of safety and efficacy. Our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production, and clinical-regulatory development. On September 25, 2018, we received regulatory approval for the marketing of UDENYCA(TM) (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission. On November 2, 2018, the U.S. Food and Drug Administration ("FDA") approved our biologics license application ("BLA") for UDENYCA(TM) as a biosimilar to Neulasta. We initiated U.S. ... More ...
Nasdaq Official Price
Jul. 17, 2019
Jul. 17, 2019